Friday 6 November 2026 Export KNSA’s income statement to Excel — free account

Kiniksa Pharmaceuticals International, plc

KNSA Healthcare Drug Manufacturers Specialty & Generic

Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024.

Revenue: +58.1%
EPS: +142.2%
Free cash flow: +43.5%

Quarter to September 2026, against a year earlier

94.12 5.78 +6.54%

Follow KNSA

Alert me

Market cap: $6.9B
P/E: 62.1×
Fwd P/E: 67.8×
Dividend yield: —
F-score: 8/9
Altman Z: 10.35
Beneish M: −3.16
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Kiniksa Pharmaceuticals International, plc 10-Q filed Oct 27, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed Oct 27, 2026 · accepted 4:36 PM ET · Document on sec.gov · Filing index

Red flags

Inventory outpacing revenue Oct 27, 2026
Inventory grew 161.0% while revenue grew 58.1% year over year

10-Q filed Oct 27, 2026 · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Oct 28, 2025: 23 added · 28 removed · 46 modified; 5 with only figures updated

Kiniksa Pharmaceuticals International, plc 10-Q filed Oct 27, 2026

Red flags

What changed

Stockrow Weekly